Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Termino C 11475 AB
AB
Dissolved
Org 5593226532
Research and experimental development on biotechnology
· NACE 7211
Est. 2021
0 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on biotechnology
/
Termino C 11475 AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
2M
4M
6M
8M
3M
2021
7M
2022
7M
2023
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
1M
2022
1M
2023
Income statement
SEK thousands
Item
2021
2022
2023
Revenue
3 426
6 897
6 812
Staff expenses
—
—
—
EBITDA
207
553
876
Depreciation & amort.
−0
−112
−445
EBIT
207
441
431
Net financials
—
−1
2
Profit before tax
208
439
433
Tax
−43
−91
−89
Net profit
165
348
344
Balance sheet
SEK thousands
Item
2021
2022
2023
Total assets
3 318
2 545
2 817
Equity
190
538
882
Long-term debt
0
0
0
Short-term debt
3 128
2 007
1 935
Total debt
3 128
2 007
1 935
Financial ratios
5-year trend
EBITDA margin
12.9%
This company
15.8%
Market median
-18% vs market
2021
2023
Equity ratio
31.3%
This company
38.2%
Market median
+18% vs market
2021
2023
Return on equity
39.0%
This company
18.4%
Market median
+112% vs market
2021
2023
Net profit margin
5.0%
This company
8.1%
Market median
-38% vs market
2021
2023
Asset turnover
2.42×
This company
1.12×
Market median
+116% vs market
2021
2023
Debt / equity
2.19×
This company
0.62×
Market median
-253% vs market
2021
2023
Annual reports & filings
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-06-01 – 2021-12-31
View
PDF
More on Termino C 11475 AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
